Creo
Medical Group plc
("Creo"
the "Company" or the "Group")
Microwave Lung Ablation
Update
Creo Medical Group plc (AIM: CREO),
the medical device company focused on the emerging field of
minimally invasive surgical endoscopy for pre-cancer and cancer
patients, announces progress with its MicroBlate Flex
device.
Professor Pallav Shah and Dr
Christopher Orton, of the Royal Brompton Hospital, have become the
first specialists in the world to perform a robotic guided
microwave ablation of lung tissue in the same sitting as a
diagnostic procedure. Creo's MicroBlate Flex device was used to
perform the procedure.
In a recent announcement, Professor
Shah and his team reported that microwave ablation was used to
ablate a 27mm cancerous nodule in a patient's lung. The procedure
took place at the Royal Brompton Hospital in London and is reported
to have taken 3 minutes.
Dr Orton commented: "The potential to combine the diagnosis,
staging and treatment of lung cancer in one procedure offers
significant benefit to patients."
Link:
https://www.rbhh-specialistcare.co.uk/news/ion-robot-lung-tumour
Craig
Gulliford, Chief Executive Officer of Creo,
said: "Creo has been
pioneering minimally invasive surgical endoscopy for pre-cancer and
cancer patients for years, and implementing our technology into
robotic application is a key goal for us as the adoption of this
technology continues to grow exponentially.
"We are incredibly proud that our MicroBlate Flex technology
has been able to make this world-first possible. The potential for
these technologies to combine precise robotically guided lung
cancer diagnosis with the ablation of cancerous tissue in one
session is transformational. Not only could this dramatically
improve outcomes for lung cancer patients, but it has the potential
to do away with long and worrying delays between diagnosis and
treatment. This is the beginning of an exciting program and the
team have done a terrific job in reaching this
point."
Enquiries:
Creo Medical
Group plc
|
www.creomedical.com
|
Richard Rees (CFO)
|
+44 (0)1291 606
005
|
|
|
Cavendish
Capital Markets Limited
|
+44 (0)20 7397
8900
|
Stephen Keys / Camilla Hume (NOMAD)
|
|
Michael Johnson (Sales)
|
|
|
|
Deutsche Numis
(Joint Broker)
Freddie Barnfield / Duncan Monteith / Euan
Brown
|
+44 (0)20
7260 1000
|
|
|
Walbrook
PR
|
Tel: +44
(0)20 7933 8780 or
creo@walbrookpr.com
|
Paul McManus / Sam Allen
Phillip Marriage
|
Mob: +44
(0)7980 541 893 / +44 (0)7502 558 258
+44
(0)7867 984 082
|
About Creo
Medical
Creo Medical is a medical device company
focused on the development and commercialisation of minimally
invasive electrosurgical devices, bringing advanced energy to
endoscopy.
The Company's vision is to improve patient
outcomes through the development and commercialisation of a suite
of electrosurgical medical devices, each enabled by CROMA, powered
by Kamaptive. The Group has developed the CROMA powered by
Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically
adapt to patient tissue during procedures such as resection,
dissection, coagulation and ablation of tissue. Kamaptive
technology provides clinicians with increased flexibility,
precision and controlled surgical solutions. CROMA currently
delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for
controlled coagulation and ablation via a single accessory port.
This technology, combined with the Group's range of patented
electrosurgical devices, is designed to provide clinicians with
flexible, accurate and controlled clinical solutions. The Directors
believe the Company's technology can impact the landscape of
surgery and endoscopy by providing a safer, less-invasive and more
cost-efficient option for procedures.
For more information, please refer to the
website www.creomedical.com